Navigation Links
Older patients with 1 type of heart failure may receive little or no benefit from drugs
Date:3/12/2009

LOS ANGELES (EMBARGOED UNTIL: 9 a.m. EST, March 12, 2009) People over 80 years of age suffering from a certain type of heart failure do not appear to benefit from most commonly prescribed heart medications, according to a study conducted at the Cedars-Sinai Heart Institute and published in the March 15 issue of The American Journal of Cardiology.

"The American population continues to live longer lives, often surviving with heart failure and other chronic conditions, but patients in this age range are typically excluded from medical research. Our review of 142 patient cases found that medications had little if any beneficial effect on five-year survival or rehospitalization for heart problems among elderly patients who have heart failure but an ejection fraction of at least 50 percent," said Cedars-Sinai Heart Institute cardiologist Ernst R. Schwarz, M.D., Ph.D., the article's senior author.

Ejection fraction is a measure of the pumping capacity of the left ventricle, the main pumping chamber of the heart. Heart failure with "preserved ejection fraction" a prevalent condition in the geriatric population is characterized by the heart contracting well but failing to relax, which prevents the chamber from properly filling with blood. Often termed "diastolic heart failure," this type of heart failure is more prominent than other forms among the elderly, women, and obese people but, like other types of heart failure, it typically has a poor prognosis and a very high mortality rate.

The authors noted that while the study found no proven benefit for drug therapy in this group of patients, cardiovascular medications are often prescribed, at both financial and physiologic cost. They urge special caution in prescribing digoxin and diuretics medications that are often used to treat congestive heart failure and other cardiac conditions because the study showed a trend toward increased mortality.

The average age of patients in this study was 87 years at the time of initial hospitalization with heart failure; 31 percent of the subjects were men. Sixty-nine percent of the patients died during the five-year follow-up, and none of the drug therapies statins, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, beta blockers, diuretics, calcium channel blockers, nitrates, and digoxin appeared to make a significant difference in which patients survived and which did not.

"The risk of adverse drug effects in the geriatric population is high. Because older patients may be taking multiple medications for a variety of medical conditions, and because drugs may affect older people differently than they do younger people, it is important for physicians to prescribe heart medications judiciously and account for a different and often more severe side effect spectrum" said Schwarz, professor of medicine at Cedars-Sinai Medical Center, medical director of the Cardiac Support Program and co-director of the Heart Transplant Program at the Cedars-Sinai Heart Institute. The study points out that more research is needed to evaluate the effects of therapies among the very elderly patients with heart failure.


'/>"/>

Contact: Sally Stewart
sally.stewart@cshs.org
310-248-6566
Cedars-Sinai Medical Center
Source:Eurekalert

Related medicine news :

1. Ability to cope with stress can increase good cholesterol in older white men, study finds
2. Many Older Americans Have Active Sex Lives
3. Good Cholesterol Wont Help Heavy-Drinking Older Men
4. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
5. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
6. Frequent alcohol consumption increases cancer risk in older women
7. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
8. ISS and Glass Lewis Recommend Cholestech Stockholders Vote FOR Merger
9. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
10. Drug-free treatments offer hope for older people in pain
11. United Medicorp, Inc.s Shareholders Approve All Proposals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... ... Philpart, senior director at PolicyLink, will be the keynote speaker at its second ... and Men of Color Framework, which develops comprehensive strategies to create and expand ...
(Date:2/21/2017)... ... February 21, 2017 , ... Support of value-based care ... the secure exchange of data across industry solutions, Fogo Data Centers announces the launch ... community. A healthy community is one in which all systems work well, work ...
(Date:2/21/2017)... ... February 21, 2017 , ... HIMSS is ... connected care demonstration spanned multiple health information systems including OpenEMR, EMRDirect, and ... providers have no Health Information Exchange outside of faxing. Medal’s innovative technology “meets ...
(Date:2/20/2017)... ... February 20, 2017 , ... A new digital ... are called back for additional examinations without sacrificing cancer detection, according to a ... the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for use ...
(Date:2/20/2017)... ... February 20, 2017 , ... Scrubbing in for his first ... Dr. Christopher Pezzi remembers the excitement of the surgeon training him. , “He was ... to do this? Don’t tell anyone, but I would do it for free,’” Dr. ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Feb. 21, 2017  International Isotopes Inc. (OTCQB: INIS) ... placement with certain investors for approximately $3.4 million of ... Series C Convertible Redeemable Preferred Stock (the "Series C ... annual rate of 6% and is convertible into common ... use the proceeds for operating capital, to pay off ...
(Date:2/21/2017)... , Feb. 21, 2017 Research and Markets ... Devices - Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... , Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. Also, a ...
(Date:2/21/2017)... 21, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Uterine cancer Drugs Price Analysis and Strategies ... cancer market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Uterine cancer ...
Breaking Medicine Technology: